

# Laura Evangelista

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5246410/publications.pdf>

Version: 2024-02-01

195  
papers

3,259  
citations

212478

28  
h-index

223390

49  
g-index

200  
all docs

200  
docs citations

200  
times ranked

4125  
citing authors

#	ARTICLE	IF	CITATIONS
1	FDG PET/CT Volume-Based Quantitative Data and Survival Analysis in Breast Cancer Patients: A Systematic Review of the Literature. <i>Current Medical Imaging</i> , 2023, 19, .	0.4	10
2	Impact on the long-term prognosis of FDG PET/CT in luminal-A and luminal-B breast cancer. <i>Nuclear Medicine Communications</i> , 2022, 43, 212-219.	0.5	8
3	PET/MR for evaluation of musculoskeletal malignancies. <i>Clinical and Translational Imaging</i> , 2022, 10, 71-83.	1.1	1
4	PET/MR in recurrent glioblastoma patients treated with regorafenib: [ <sup>18</sup> F]FET and DWI-ADC for response assessment and survival prediction. <i>British Journal of Radiology</i> , 2022, 95, 20211018.	1.0	13
5	Challenges in theragnostics. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 65, .	0.4	1
6	Theragnostics applications and challenges. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 65, 297-298.	0.4	2
7	PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature. <i>Cancers</i> , 2022, 14, 1770.	1.7	21
8	[ <sup>68</sup> Ga]Ga-PSMA Versus [ <sup>18</sup> F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2022, 5, 273-282.	2.6	37
9	Radiomic features as biomarkers of soft tissue paediatric sarcomas: preliminary results of a PET/MR study. <i>Radiology and Oncology</i> , 2022, 56, 138-141.	0.6	4
10	Gender issues in the nuclear medicine community: results from a survey promoted by the EANM Women Empowerment Task Force. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2106-2112.	3.3	5
11	An incidental finding behind adrenal incidentaloma. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2022, 2022, .	0.2	0
12	PET/MRI in prostate cancer: a systematic review and meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 859-873.	3.3	85
13	An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1522-1537.	3.3	6
14	Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2871-2882.	3.3	11
15	PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1709-1711.	3.3	1
16	The role of 18F-Fluorodeoxyglucose PET/CT in restaging patients with small cell lung cancer: a systematic review. <i>Nuclear Medicine Communications</i> , 2021, 42, 839-845.	0.5	3
17	Comparison of MRI, PET, and 18F-choline PET/MRI in patients with oligometastatic recurrent prostate cancer. <i>Abdominal Radiology</i> , 2021, 46, 4401-4409.	1.0	5
18	Skeletal Muscle Metastases in HCC Revealed by 18F-Choline PET/CT. <i>Clinical Nuclear Medicine</i> , 2021, Publish Ahead of Print, e592-e593.	0.7	0

#	ARTICLE	IF	CITATIONS
19	The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review. <i>Annals of Nuclear Medicine</i> , 2021, 35, 767-776.	1.2	26
20	Women in nuclear medicine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2678-2679.	3.3	10
21	Re: Hendrik Van Poppel, René Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. <i>Eur Urol</i> 2021;79:327-329. <i>European Urology</i> , 2021, 80, e24-e27.	0.9	0
22	State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation. <i>Clinical and Translational Imaging</i> , 2021, 9, 299-339.	1.1	70
23	An Incidental Pancreatic Finding at 18F-Choline PET/CT: Chronic Mass-Forming Pancreatitis. <i>Diagnostics</i> , 2021, 11, 1490.	1.3	0
24	Gender balance in the editorial board of nuclear medicine journals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3749-3750.	3.3	2
25	Value of 18F-fluorocholine PET/CT in predicting response to radical radiotherapy in patients with localized prostate cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 30, 71-77.	0.9	2
26	Detection rate of 18F-Choline positron emission tomography/computed tomography in patients with non-metastatic hormone sensitive and castrate resistant prostate cancer. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, , .	0.4	4
27	[18F]FDG PET/MRI in rectal cancer. <i>Annals of Nuclear Medicine</i> , 2021, 35, 281-290.	1.2	20
28	An Incidental Uptake of 18F-Choline at PET/CT in Gastric Neuroendocrine Tumor. <i>Clinical Nuclear Medicine</i> , 2021, 46, e238-e239.	0.7	2
29	Additional Value of PET Radiomic Features for the Initial Staging of Prostate Cancer: A Systematic Review from the Literature. <i>Cancers</i> , 2021, 13, 6026.	1.7	16
30	The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer. <i>European Urology Focus</i> , 2020, 6, 146-150.	1.6	25
31	10-Year Clinical Experience With 18F-Choline PET/CT. <i>Clinical Nuclear Medicine</i> , 2020, 45, 594-603.	0.7	6
32	Re: Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, et al. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomized, Multicenter Study. <i>Lancet</i> 2020;395:1208-1216. <i>European Urology Oncology</i> , 2020, 3, 713.	2.6	2
33	18F-choline PET/CT and PET/MRI in primary and recurrent hyperparathyroidism: a systematic review of the literature. <i>Annals of Nuclear Medicine</i> , 2020, 34, 601-619.	1.2	42
34	18F-FDG PET/MRI in adult sarcomas. <i>Clinical and Translational Imaging</i> , 2020, 8, 405-412.	1.1	10
35	We will continue to grow up together!. <i>Clinical and Translational Imaging</i> , 2020, 8, 231-231.	1.1	0
36	Somatostatin Receptor PET/CT Imaging for the Detection and Staging of Pancreatic NET: A Systematic Review and Meta-Analysis. <i>Diagnostics</i> , 2020, 10, 598.	1.3	28

#	ARTICLE	IF	CITATIONS
37	Clinical Impact of 18F-FDG PET/CT in the Diagnostic Workup of Pancreatic Ductal Adenocarcinoma: A Systematic Review. <i>Diagnostics</i> , 2020, 10, 1042.	1.3	7
38	The Multicenter Italian Trial Assesses the Performance of FDG-PET /CT Related to Pre-Test Cancer Risk in Patients with Solitary Pulmonary Nodules and Introduces a Segmental Thoracic Diagnostic Strategy. <i>Current Radiopharmaceuticals</i> , 2020, 13, 243-248.	0.3	3
39	Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review. <i>Clinical Imaging</i> , 2020, 67, 113-116.	0.8	35
40	What Is the Role of Imaging in Cancers?. <i>Cancers</i> , 2020, 12, 1494.	1.7	1
41	PET and SPECT Imaging in the SARS-CoV-2 Pandemic. <i>Current Radiopharmaceuticals</i> , 2020, 13, 87-88.	0.3	1
42	PET/CT and the Response to Immunotherapy in Lung Cancer. <i>Current Radiopharmaceuticals</i> , 2020, 13, 177-184.	0.3	17
43	Molecular imaging and immunotherapy. <i>International Journal of Biological Markers</i> , 2020, 35, 37-41.	0.7	2
44	Role of Sentinel Lymph Node Biopsy in Patients with Locally Advanced Breast Cancer, after Neoadjuvant Chemotherapy. <i>European Journal of Surgical Oncology</i> , 2020, 46, e46.	0.5	0
45	Molecular Imaging of Pulmonary Inflammation and Infection. <i>International Journal of Molecular Sciences</i> , 2020, 21, 894.	1.8	18
46	Re: A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT. <i>Clinical Nuclear Medicine</i> , 2020, 45, e219-e220.	0.7	0
47	Copper, PET/CT and prostate cancer: a systematic review of the literature. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 382-392.	0.4	6
48	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020, 12, 1303.	1.7	6
49	The Bone Pathway: 223Ra-Dichloride. , 2020, , 179-192.		0
50	The Imaging of Lung Cancer: A Complete Vision. <i>Current Radiopharmaceuticals</i> , 2020, 13, 165-165.	0.3	0
51	The War Is Opened: PSMA vs. 64CuCl <sub>2</sub> vs. Choline PET/CT. <i>Journal of Nuclear Medicine</i> , 2019, 60, 292.1-292.	2.8	1
52	Targeting prostate cancer with the anti-PSMA scFvD2B: a theranostic promise for nuclear medicine. <i>Clinical and Translational Imaging</i> , 2019, 7, 295-301.	1.1	1
53	Management of hyperglycemia in oncological patients scheduled for an FDG-PET/CT examination. <i>Clinical and Translational Imaging</i> , 2019, 7, 447-450.	1.1	3
54	Immunotherapy and 18F-FDG PET/CT: standardised procedures are needed. <i>Clinical and Translational Imaging</i> , 2019, 7, 313-315.	1.1	8

#	ARTICLE	IF	CITATIONS
55	18F-Facbc in Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1348.	1.7	34
56	Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 1. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 74-79.	2.0	18
57	18F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosisâ€”A Multicenter Retrospective Study. <i>Cancers</i> , 2019, 11, 700.	1.7	23
58	Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 117-124.	2.0	20
59	Head-to-head comparison between 18F-FDG PET/CT and PET/MRI in breast cancer. <i>Clinical and Translational Imaging</i> , 2019, 7, 99-104.	1.1	5
60	The Role of 18F-FDG PET/CT in Staging and Prognostication of Mantle Cell Lymphoma: An Italian Multicentric Study. <i>Cancers</i> , 2019, 11, 1831.	1.7	18
61	18F-FDG PET/CT in non-small-cell lung cancer patients. <i>Nuclear Medicine Communications</i> , 2019, 40, 802-807.	0.5	63
62	Pleural Mesothelioma Detects by 18F-Choline PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2019, 44, e116-e117.	0.7	4
63	18F-Choline PET/CT in Leptomeningeal Breast Cancer Metastases. <i>Clinical Nuclear Medicine</i> , 2019, 44, e96-e97.	0.7	6
64	<sup>64</sup> CuCl <sub>2</sub> PET/CT in a Hyperfunctioning Parathyroid Gland. <i>Clinical Nuclear Medicine</i> , 2019, 44, e449-e452.	0.7	1
65	Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma. <i>Nuclear Medicine Communications</i> , 2019, 40, 808-814.	0.5	8
66	The prediction of response to immunotherapy in non-small cell lung cancer patients by 18F-FDG PET/CT. <i>Journal of Thoracic Disease</i> , 2019, 11, E221-E223.	0.6	6
67	Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e187-e194.	0.9	14
68	<sup>68</sup> Ga-dotatoc vs. 18F-FDG vs. radiolabelled PSMA PET/CT in renal cancer patients. <i>Annals of Translational Medicine</i> , 2019, 7, S150-S150.	0.7	3
69	Comparison Between 18F-Dopa and 18F-Fet PET/CT in Patients with Suspicious Recurrent High Grade Glioma: A Literature Review and Our Experience. <i>Current Radiopharmaceuticals</i> , 2019, 12, 220-228.	0.3	8
70	The effects of androgen deprivation therapy on the 18F-Chcoline uptake in prostate cancer patients undergoing neoadjuvant treatment. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 278-283.	0.4	7
71	The future of choline PET in the era of prostate specific membrane antigen. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 19-28.	0.4	10
72	Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5â€”ng/ml. <i>Nuclear Medicine Communications</i> , 2018, 39, 260-267.	0.5	5

#	ARTICLE	IF	CITATIONS
73	Editorial Comment. Journal of Urology, 2018, 199, 733-733.	0.2	0
74	Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study. Abdominal Radiology, 2018, 43, 2391-2399.	1.0	23
75	Will 68 Ga PSMA-radioligands be the only choice for nuclear medicine in prostate cancer in the near future? A clinical update. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 103-109.	0.1	0
76	Ground glass pulmonary nodules: their significance in oncology patients and the role of computer tomography and 18F-fluorodeoxyglucose positron emission tomography. European Journal of Hybrid Imaging, 2018, 2, 2.	0.6	11
77	Italian Multicenter Study on Accuracy of 18 F-FDG PET/CT in Assessing Bone Marrow Involvement in Pediatric Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e267-e273.	0.2	15
78	¿Constituirán en el futuro los radioligandos de 68 Ga-PSMA la única elección de la Medicina Nuclear para el cáncer de próstata? Actualización clínica. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 103-109.	0.0	3
79	The role of PET/CT in the evaluation of patients with urothelial cancer: a systematic review and meta-analysis. Clinical and Translational Imaging, 2018, 6, 77-89.	1.1	3
80	Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid. Annals of Nuclear Medicine, 2018, 32, 7-15.	1.2	17
81	Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 85-94.	3.3	20
82	Diagnostic value of contrast-enhanced CT combined with 18-FDG PET in patients selected for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Abdominal Radiology, 2018, 43, 1094-1100.	1.0	7
83	Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary. Frontiers in Oncology, 2018, 8, 581.	1.3	7
84	18F-FDG or 68Ga/18F-PSMA PET/CT in recurrent renal cancer?. Clinical and Translational Imaging, 2018, 6, 329-330.	1.1	4
85	Translational molecular imaging in exocrine pancreatic cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2442-2455.	3.3	17
86	Re: Response Assessment of 223Ra Treatment: Should a Fluorocholine PET/CT Be Performed?. Clinical Nuclear Medicine, 2018, 43, 867-868.	0.7	4
87	Prostate cancer imaging: when the game gets tough, the hard one gets done!. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2032-2034.	3.3	0
88	Targeted Therapy with Radium-223 of Bone Metastases. , 2018, , 365-377.		0
89	Italian Tailored Assessment of Lung Indeterminate Accidental Nodule by Proposing a Segmental Pet/Computed Tomography (S-Pet/Ct): Rationale And Study Design of a Retrospective, Multicenter Trial. Current Radiopharmaceuticals, 2018, 11, 46-49.	0.3	3
90	Performance of FDG-PET/CT in solitary pulmonary nodule based on pre-test likelihood of malignancy: results from the ITALIAN retrospective multicenter trial. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1898-1907.	3.3	17

#	ARTICLE	IF	CITATIONS
91	Risk-related 18F-FDG PET/CT and new diagnostic strategies in patients with solitary pulmonary nodule: the ITALIAN multicenter trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1908-1914.	3.3	12
92	Ectopic Salivary Gland in a Patient With Prostate Cancer at 18F-Choline PET/CT. <i>Clinical Nuclear Medicine</i> , 2018, 43, 593-594.	0.7	0
93	MP77-09 EARLY AND LATE IMAGES OF 18F-CHOLINE (FCH) PET/CT FOR THE DETECTION OF PROSTATIC FOSSAE RECURRENCES IN PROSTATE CANCER WITH A BIOCHEMICAL FAILURE (PSA> 2 NG/ML). <i>Journal of Urology</i> , 2018, 199, .	0.2	1
94	Association between semiquantitative PET parameters and molecular subtypes of breast invasive ductal carcinoma. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 101-111.	0.4	3
95	Prostate cancer imaging and therapy. , 2018, , .		0
96	Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer. <i>Clinical Imaging</i> , 2017, 43, 110-116.	0.8	3
97	Diagnostic and prognostic impact of fluorine-18-fluorodeoxyglucose PET/CT in preoperative and postoperative setting of breast cancer patients. <i>Nuclear Medicine Communications</i> , 2017, 38, 537-545.	0.5	12
98	Pitfalls and artifacts of FDG PET/CT in recurrent breast cancer patients. <i>Clinical and Translational Imaging</i> , 2017, 5, 169-182.	1.1	0
99	Clinical results and economic considerations of 68 Ga-PSMA and radiolabeled choline in prostate cancer. <i>Nuclear Medicine and Biology</i> , 2017, 50, 47-49.	0.3	11
100	Alternative imaging strategy of solitary pulmonary nodule by FDG PET/CT. <i>European Journal of Radiology</i> , 2017, 90, 188-191.	1.2	6
101	The new era of cancer immunotherapy: what can molecular imaging do to help?. <i>Clinical and Translational Imaging</i> , 2017, 5, 299-301.	1.1	8
102	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2017, , 883-923.		0
103	Re: Marlon Perera, Nathan Papa, Daniel Christidis, et al. Sensitivity, Specificity, and Predictors of Positive 68 Ga-PSMA Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. <i>Eur Urol</i> 2016;70:926-937. <i>European Urology</i> , 2017, 71, e64-e65.	0.9	0
104	Biochemical and Pathophysiological Premises to Positron Emission Tomography With Choline Radiotracers. <i>Journal of Cellular Physiology</i> , 2017, 232, 270-275.	2.0	28
105	Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study. <i>Cancer Management and Research</i> , 2017, Volume 9, 789-800.	0.9	16
106	Imaging of Glycolysis with 18F-FDG PET. , 2017, , 87-94.		0
107	Approaches for Assessment of Response of Bone Metastases to Therapies. , 2017, , 223-249.		0
108	Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 205-215.	0.4	5

#	ARTICLE	IF	CITATIONS
109	Re. Clinical Nuclear Medicine, 2016, 41, 746.	0.7	1
110	Radiolabeled choline PET/CT before salvage lymphadenectomy dissection. Nuclear Medicine Communications, 2016, 37, 1223-1231.	0.5	21
111	Reply to Egesta Lopci, Arturo Chiti, and Massimo Lazzeri's Letter to the Editor re: Laura Evangelista, Alberto Briganti, Stefano Fanti, et al. New Clinical Indications for 18F/11C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Eur Urol 2016;70:161-75. European Urology. 2016, 70. e114-e115.	0.9	2
112	Editorial Comment. Journal of Urology, 2016, 195, 1442-1443.	0.2	0
113	Can 68GA-PSMA or radiolabeled choline PET/CT guide salvage lymph node dissection in recurrent prostate cancer?. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1407-1409.	3.3	4
114	A Solitary Metastasis for a Malignant Schwannoma in the Gallbladder Detected by 18F-FDG PET/CT. Clinical Nuclear Medicine, 2016, 41, 666-667.	0.7	5
115	Radiolabelled choline and FDG PET/CT: two alternatives for the assessment of lymph node metastases in patients with upper urinary tract urothelial carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 576-577.	3.3	7
116	Nuclear medicine and the revolution in the modern management of castration-resistant prostate cancer patients: from 223Ra-dichloride to new horizons for therapeutic response assessment. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 5-7.	3.3	6
117	New Clinical Indications for 18 F/ 11 C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. European Urology, 2016, 70, 161-175.	0.9	184
118	Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1546-1562.	3.3	37
119	Prostate-specific antigen and radiolabelled choline PET/CT for the assessment of response to therapy: synergy or conflicting?. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 200-201.	3.3	3
120	Predictive value of 18F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 404-413.	3.3	47
121	Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 464-473.	3.3	79
122	Diagnostic and Prognostic Value of 18F-FDG PET/CT in Male Breast Cancer: Results From a Bicentric Population. Current Radiopharmaceuticals, 2016, 9, 169-177.	0.3	6
123	18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis. Current Radiopharmaceuticals, 2016, 9, 244-257.	0.3	46
124	Role of molecular imaging in the management of patients affected by inflammatory bowel disease: State-of-the-art. World Journal of Radiology, 2016, 8, 829.	0.5	16
125	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2016, , 1-41.		0
126	Impressive response to denosumab in a patient with bone metastatic adenocarcinoma of the stomach after 2 years of zoledronic acid. Anti-Cancer Drugs, 2015, 26, 232-235.	0.7	2



#	ARTICLE	IF	CITATIONS
127	The role of PET/CT in the evaluation of patients affected by limbic encephalitis: A systematic review of the literature. <i>Journal of Neuroimmunology</i> , 2015, 284, 44-48.	1.1	29
128	Discordance rate between radiolabelled choline PET/CT and bone scintigraphy in detecting bone metastases in patients with prostate cancer: a meta-analysis. <i>Clinical and Translational Imaging</i> , 2015, 3, 133-140.	1.1	2
129	Multicentric study on 18F-FDG-PET/CT breast incidental uptake in patients studied for non-breast malignant purposes. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2015, 34, 24-29.	0.0	5
130	Mismatch between perfusion and metabolism in locally advanced breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 803-804.	3.3	0
131	18F-fluoromethylcholine or 18F-fluoroethylcholine pet for prostate cancer imaging: which is better? A literature revision. <i>Nuclear Medicine and Biology</i> , 2015, 42, 340-348.	0.3	25
132	Gleason Score at Diagnosis Predicts the Rate of Detection of <sup>18</sup> F-Choline PET/CT Performed When Biochemical Evidence Indicates Recurrence of Prostate Cancer: Experience with 1,000 Patients. <i>Journal of Nuclear Medicine</i> , 2015, 56, 209-215.	2.8	69
133	The ability of 18F-choline PET/CT to identify local recurrence of prostate cancer. <i>Abdominal Imaging</i> , 2015, 40, 3230-3237.	2.0	27
134	Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1648-1655.	3.3	16
135	Comparison between conventional imaging (abdominal+pelvic computed tomography and bone scan) and [ <sup>18</sup> F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- to high-risk prostate cancer: A retrospective analysis. <i>Scandinavian Journal of Urology</i> , 2015, 49, 345-353.	0.6	56
136	Conflicting or complementary role of computed tomography (CT) and positron emission tomography (PET)/CT in the assessment of thymic cancer and thymoma: our experience and literature review. <i>Thoracic Cancer</i> , 2015, 6, 433-442.	0.8	16
137	Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients. <i>Journal of the Turkish German Gynecology Association</i> , 2015, 16, 137-144.	0.2	27
138	Correlation between Cancer Antigen 15.3 Value and Qualitative and Semiquantitative Parameters of Positron Emission Tomography/Computed Tomography in Breast Cancer Patients. <i>Current Radiopharmaceuticals</i> , 2014, 7, 20-28.	0.3	3
139	Nuclear Imaging and Early Breast Cancer Detection. <i>Current Radiopharmaceuticals</i> , 2014, 7, 29-35.	0.3	4
140	Molecular imaging: the emerging role of optical imaging in nuclear medicine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2150-2153.	3.3	15
141	Is Radiocholine PET/CT Already Clinically Useful in Patients with Prostate Cancer?. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1401-1403.	2.8	15
142	Comparison between anatomical cross-sectional imaging and 18F-FDG PET/CT in the staging, restaging, treatment response, and long-term surveillance of squamous cell head and neck cancer. <i>Nuclear Medicine Communications</i> , 2014, 35, 123-134.	0.5	44
143	18F-fluorodeoxyglucose PET/computed tomography and risk stratification after neoadjuvant treatment in esophageal cancer patients. <i>Nuclear Medicine Communications</i> , 2014, 35, 160-168.	0.5	5
144	FDG Avidity at PET/CT During Adjuvant Hormonal Therapy in Patients With Breast Cancer. <i>Clinical Nuclear Medicine</i> , 2014, 39, e135-e141.	0.7	0

#	ARTICLE	IF	CITATIONS
145	Microdosimetric measurements in the thermal neutron irradiation facility of LENA reactor. Applied Radiation and Isotopes, 2014, 88, 147-152.	0.7	11
146	Therapeutic impact of 18F-FDG PET/CT in recurrent differentiated thyroid carcinoma. Radiologia Medica, 2014, 119, 97-102.	4.7	7
147	MRI and 18F-FDG PET/CT in monitoring the response to neoadjuvant chemotherapy: is it necessary to appropriately select the patients?. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1511-1514.	3.3	0
148	Use of a portable gamma camera for guiding surgical treatment in locally advanced breast cancer in a post-neoadjuvant therapy setting. Breast Cancer Research and Treatment, 2014, 146, 331-340.	1.1	9
149	Reclassification of cardiovascular risk by myocardial perfusion imaging in diabetic patients with abnormal resting electrocardiogram. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 588-593.	1.1	6
150	Follow-up of patients with early breast cancer: Is it time to rewrite the story?. Critical Reviews in Oncology/Hematology, 2014, 91, 130-141.	2.0	36
151	Preliminary monocentric results of biological characteristics of pregnancy associated breast cancer. Breast, 2014, 23, 19-25.	0.9	13
152	Indeterminate Lung Nodules in Cancer Patients: Pretest Probability of Malignancy and the Role of <sup>18</sup> F-FDG PET/CT. American Journal of Roentgenology, 2014, 202, 507-514.	1.0	18
153	<sup>18</sup> F-DOPA and <sup>18</sup> F-FDG PET/CT, Scintigraphic Localization and Radioguided Surgery of Recurrent Medullary Thyroid Cancer: Two Case Reports. Current Radiopharmaceuticals, 2014, 7, 133-137.	0.3	3
154	Small-bowel MRI in children and young adults with Crohn disease: retrospective head-to-head comparison of contrast-enhanced and diffusion-weighted MRI. Pediatric Radiology, 2013, 43, 103-114.	1.1	96
155	Comparative studies of radiolabeled choline positron emission tomography, histology of primary tumor and other imaging modalities in prostate cancer: a systematic review and meta-analysis. Clinical and Translational Imaging, 2013, 1, 99-109.	1.1	9
156	Utility of Choline Positron Emission Tomography/Computed Tomography for Lymph Node Involvement Identification in Intermediate- to High-risk Prostate Cancer: A Systematic Literature Review and Meta-analysis. European Urology, 2013, 63, 1040-1048.	0.9	251
157	Molecular pathways and molecular imaging in breast cancer: An update. Nuclear Medicine and Biology, 2013, 40, 581-591.	0.3	14
158	Boron neutron capture therapy and 18F-labelled borophenylalanine positron emission tomography: A critical and clinical overview of the literature. Applied Radiation and Isotopes, 2013, 74, 91-101.	0.7	36
159	Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer. Clinical Nuclear Medicine, 2013, 38, 305-314.	0.7	255
160	New Issues for Copper-64: from Precursor to Innovative Pet Tracers in Clinical Oncology. Current Radiopharmaceuticals, 2013, 6, 117-123.	0.3	22
161	The future of imaging for breast cancer recurrence. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2013, 57, 381-2.	0.4	0
162	Positron emission tomography/computed tomography and esophageal cancer in the clinical practice: How does it affect the prognosis?. Journal of Cancer Research and Therapeutics, 2012, 8, 619.	0.3	14

#	ARTICLE	IF	CITATIONS
163	Diagnostic and prognostic value of gated myocardial perfusion single-photon emission computed tomography in low-risk patients with left bundle-branch block. <i>Nuclear Medicine Communications</i> , 2012, 33, 491-497.	0.5	5
164	How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals. <i>Nuclear Medicine Communications</i> , 2012, 33, 679-688.	0.5	18
165	Colorectal cancer. <i>Nuclear Medicine Communications</i> , 2012, 33, 780-782.	0.5	1
166	Tumor Markerâ€œGuided PET in Breast Cancer Patientsâ€œA Recipe for a Perfect Wedding. <i>Clinical Nuclear Medicine</i> , 2012, 37, 467-474.	0.7	26
167	Indeterminate pulmonary nodules on CT images in breast cancer patient: The additional value of 18Fâ€œFDG PET/CT. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2012, 56, 417-424.	0.9	15
168	Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. <i>Cancer</i> , 2012, 118, 5454-5462.	2.0	55
169	Early bone marrow metastasis detection: The additional value of FDG-PET/CT vs. CT imaging. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 448-453.	2.5	50
170	Risk stratification and prognostic assessment by myocardial perfusion-gated SPECT in patients with left bundle-branch block and low-intermediate cardiac risk. <i>Annals of Nuclear Medicine</i> , 2012, 26, 559-570.	1.2	8
171	Diffusion-weighted MRI for detection and differentiation of musculoskeletal tumorous and tumor-like lesions in pediatric patients. <i>World Journal of Pediatrics</i> , 2012, 8, 342-349.	0.8	46
172	Prognostic value of myocardial perfusion scintigraphy in elderly patients with hypertension: a 10-year follow-up analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1570-1580.	3.3	3
173	PET/CT imaging in gynecologic malignancies: A critical overview of its clinical impact and our retrospective single center analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 84-98.	2.0	10
174	Myocardial perfusion imaging and risk classification for coronary heart disease in diabetic patients. The IDIS study: a prospective, multicentre trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 387-395.	3.3	38
175	Can FDG PET/CT monitor the response to hormonal therapy in breast cancer patients?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 446-449.	3.3	4
176	Nuclear Imaging and Early Breast Cancer Detection. <i>Journal of Cancer Science &amp; Therapy</i> , 2012, 01, .	1.7	0
177	Comparison of 18F-FDG positron emission tomography/computed tomography and computed tomography in patients with already-treated breast cancer: diagnostic and prognostic implications. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 56, 375-84.	0.4	8
178	FDG-PET/CT and parathyroid carcinoma: Review of literature and illustrative case series. <i>World Journal of Clinical Oncology</i> , 2011, 2, 348.	0.9	75
179	Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 293-301.	3.3	45
180	Could the serial determination of Ca15.3 serum improve the diagnostic accuracy of PET/CT? Results from small population with previous breast cancer. <i>Annals of Nuclear Medicine</i> , 2011, 25, 469-477.	1.2	13

#	ARTICLE	IF	CITATIONS
181	What are the Best Ways to Reduce the False-positive Rate of 18F-FDG PET/CT in Patients with Breast Cancer?. Nuclear Medicine and Molecular Imaging, 2011, 45, 85-86.	0.6	0
182	C-reactive protein levels are associated with paraoxonase polymorphism L55M in patients undergoing cardiac SPECT imaging. Scandinavian Journal of Clinical and Laboratory Investigation, 2011, 71, 179-184.	0.6	4
183	FDG-PET/CT visualises a case of primary hyperparathyroidism in patient with GIST. Minerva Endocrinologica, 2010, 35, 193-5.	1.7	2
184	Incremental prognostic value of cardiac single-photon emission computed tomography after nitrate administration in patients with ischemic left ventricular dysfunction. Journal of Nuclear Cardiology, 2009, 16, 38-44.	1.4	10
185	Cardiac performance during exercise in hypertensive patients without ventricular hypertrophy. European Journal of Clinical Investigation, 2009, 39, 664-670.	1.7	4
186	Cardiovascular risk stratification of diabetic patients. Minerva Endocrinologica, 2009, 34, 205-21.	1.7	4
187	Impact of inducible ischemia by stress SPECT in cardiac risk assessment in diabetic patients: Rationale and design of a prospective, multicenter trial. Journal of Nuclear Cardiology, 2008, 15, 100-104.	1.4	20
188	Stress cardiac single-photon emission computed tomographic imaging late after coronary artery bypass surgery for risk stratification and estimation of time to cardiac events. Journal of Thoracic and Cardiovascular Surgery, 2008, 136, 46-51.	0.4	22
189	Single-Photon Emission Computed Tomography After Nitrate Administration Predicts Cardiac Events in Patients With Previous Myocardial Infarction and Left Ventricular Dysfunction. Journal of Cardiac Failure, 2007, 13, 765-768.	0.7	3
190	Usefulness of Stress Cardiac Single-Photon Emission Computed Tomographic Imaging Late After Percutaneous Coronary Intervention for Assessing Cardiac Events and Time to Such Events. American Journal of Cardiology, 2007, 100, 436-441.	0.7	31
191	Radionuclide Imaging in Patients with Ischemic Heart Failure. Current Medical Imaging, 2005, 1, 17-23.	0.4	0
192	Relation between wall thickening on gated perfusion SPECT and functional recovery after coronary revascularization in patients with previous myocardial infarction. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1599-1605.	3.3	13
193	Nuclear medicine and positron emission tomography imaging in cardiology. Nuclear Medicine Review, 2003, 6, 59-63.	0.3	0
194	Should FDG PET/CT or PET/MR replace WBC scan in infectious and inflammatory disease?. Clinical and Translational Imaging, 0, , 1.	1.1	1
195	18F-FDG PET/MRI in endometrial cancer: systematic review and meta-analysis. Clinical and Translational Imaging, 0, , 1.	1.1	4